Physician profile
Meredith M Hancock
NPI 1275899510
$8,629.88
in general payments reported to CMS, 2019-2025
27 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $331 · 2021: $707 · 2022: $2,794 · 2023: $1,440 · 2024: $987 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,895 · Education: $82.95 · Travel and Lodging: $25.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,895.13 |
| Education | $82.95 |
| Travel and Lodging | $25.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teladoc Health, INC. | $1,425.00 | 2022 | |
| Abbvie INC. | $1,176.54 | 2019-2025 | |
| Pfizer INC. | $818.54 | 2019-2025 | |
| Janssen Biotech, INC. | $749.76 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $660.27 | 2019-2025 | |
| Incyte Corporation | $601.45 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $424.34 | 2019-2025 | Nemluvio |
| Amgen INC. | $414.19 | 2022-2025 | Otezla, Otezla |
| Almirall LLC | $350.03 | 2023-2025 | Seysara, Klisyri, Tazorac |
| Ucb, INC. | $349.04 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $332.68 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.86 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $197.75 | 2022-2024 | Sotyktu, Sprycel |
| Sun Pharmaceutical Industries INC. | $193.75 | 2022-2023 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $192.18 | 2019-2023 | Taltz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $122.58 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.09 | 2022-2023 | Spevigo |
| Leo Pharma INC. | $36.15 | 2021-2025 | Anzupgo |
| Blueprint Medicines Corporation | $19.74 | 2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $19.61 | 2019 | |
| Nabriva Therapeutics, Plc | $19.53 | 2022 | |
| Biofrontera INC. | $18.53 | 2019-2022 | |
| Epi Health, LLC | $17.91 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.72 | 2019 | |
| Kerecis Limited | $14.34 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Organon LLC | $6.30 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.